Abdel Khalik Hassaan, Shanmugaraj Ajaykumar, Ekhtiari Seper, Horner Nolan S, Gazendam Aaron, Simunovic Nicole, Ayeni Olufemi R
Department of Surgery, Division of Orthopaedics, McMaster University, Hamilton, Ontario, Canada.
University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
Knee Surg Sports Traumatol Arthrosc. 2025 Mar;33(3):856-864. doi: 10.1002/ksa.12403. Epub 2024 Aug 6.
To identify risk factors associated with increased postoperative opioid consumption and inferior pain outcomes following knee and shoulder arthroscopy.
Using the data set from the NonOpioid Prescriptions after Arthroscopic Surgery in Canada (NO PAin) trial, eight prognostic factors were chosen a priori to evaluate their effect on opioid consumption and patient-reported pain following arthroscopic knee and shoulder surgery. The primary outcome was the number of oral morphine equivalents (OMEs) consumed at 2 and 6 weeks postoperatively. The secondary outcome was patient-reported postoperative pain using the Visual Analogue Scale (VAS) at 2 and 6 weeks postoperatively. A multivariable linear regression was used to analyse these outcomes with eight prognostic factors as independent variables.
Tobacco usage was significantly associated with higher opioid usage at 2 (p < 0.001) and 6 weeks (p = 0.02) postoperatively. Former tobacco users had a higher 2-week (p = 0.002) and cumulative OME (p = 0.002) consumption compared to current and nonsmokers. Patients with a higher number of comorbidities (p = 0.006) and those who were employed (p = 0.006) reported higher pain scores at 6 weeks. Patients in the 'not employed/other' category had significantly lower pain scores at 6 weeks postoperatively (p = 0.046).
Former smoking status was significantly associated with increased post-operative opioid consumption following knee and shoulder arthroscopy at 2 and 6 weeks postoperatively. Increased pain was found to be significantly associated with employment status and an increasing number of comorbidities at 6 weeks postoperatively. These findings can aid clinicians in identifying and mitigating increased opioid utilization as well as worse pain outcomes in high-risk patient populations.
Level III, cohort study.
确定与膝关节和肩关节关节镜检查后阿片类药物使用量增加及疼痛结果较差相关的危险因素。
利用加拿大关节镜手术后非阿片类药物处方(NO PAin)试验的数据集,预先选择了八个预后因素,以评估它们对关节镜下膝关节和肩关节手术后阿片类药物使用及患者报告疼痛的影响。主要结局是术后2周和6周口服吗啡当量(OME)的消耗量。次要结局是术后2周和6周使用视觉模拟量表(VAS)评估的患者报告的术后疼痛。采用多变量线性回归分析这些结局,将八个预后因素作为自变量。
吸烟与术后2周(p < 0.001)和6周(p = 0.02)较高的阿片类药物使用显著相关。与当前吸烟者和不吸烟者相比,既往吸烟者术后2周(p = 0.002)和累积OME消耗量(p = 0.002)更高。合并症数量较多的患者(p = 0.006)和就业患者(p = 0.006)在6周时报告的疼痛评分更高。“未就业/其他”类别的患者术后6周疼痛评分显著较低(p = 0.046)。
既往吸烟状态与膝关节和肩关节关节镜检查术后2周和6周阿片类药物使用量增加显著相关。发现疼痛增加与术后6周的就业状态和合并症数量增加显著相关。这些发现有助于临床医生识别和减轻高危患者群体中阿片类药物使用增加以及疼痛结果较差的情况。
III级,队列研究。